Articles Tagged With: Pharmacology
-
Gabapentin vs. Duloxetine vs. Falls in Older Adults
This retrospective study examining fall risk among older adults taking gabapentin compared to duloxetine finds gabapentin users exhibit a markedly lower risk of fall-related visits at six months (hazard ratio = 0.52) yet finds no difference in the incidence of severe falls.
-
Suzetrigine Tablets (Journavx)
The U.S. Food and Drug Administration has approved suzetrigine, a first-in-class, non-opioid analgesic, to treat moderate to severe pain.
-
Noninferiority of Seven vs. 14 Days of Antibiotic Therapy for Bloodstream Infections
In this multinational, noninferiority trial that included more than 3,600 hospitalized patients with bloodstream infections from various pathogens and infectious syndromes, seven days of antibiotic therapy was noninferior to 14 days with respect to death from any cause by 90 days. Patients were excluded if they had severe immunosuppression or foci requiring prolonged treatment, or if their blood cultures yielded Staphylococcus aureus or possible contaminants. Various secondary outcomes were similar between the two groups.
-
Procalcitonin-Guided Care Leads to Shorter Duration of Antibiotics in Sepsis
In this multicenter, intervention-concealed, randomized clinical trial of 2,760 critically ill patients hospitalized with sepsis, the use of a daily procalcitonin-guided protocol resulted in shorter antibiotic duration as compared with standard care, without a significant difference in 28-day all-cause mortality. There was no significant difference in antibiotic duration between patients managed with a daily C-reactive protein-guided protocol and standard care, and the difference in all-cause mortality between these two groups was inconclusive.
-
Nemolizumab-Ilto (Nemluvio)
The U.S. Food and Drug Administration has approved nemolizumab, the first monoclonal antibody specifically targeting the interleukin-31 pathway linked to pruritus and skin inflammation associated with atopic dermatitis.
-
Tirzepatide Injection (Zepbound) for Obstructive Sleep Apnea
The U.S. Food and Drug Administration has approved tirzepatide for the treatment of moderate-to-severe sleep apnea in adults with obesity.
-
Clostridioides difficile: Reduced Susceptibility to Vancomycin?
Many sites have been reluctant to prescribe fidaxomicin as the first-line agent, despite fairly robust evidence indicating its efficacy relative to vancomycin in preventing recurrences. We still cannot predict who will do well with vancomycin and which patients are likely to relapse or to do more poorly. The gradual emergence of Clostridioides difficile with reduced vancomycin susceptibility may contribute to adverse outcomes when using this agent.
-
Revumenib Tablets (Revuforj)
The U.S. Food and Drug Administration has approved the first menin inhibitor, revumenib, for the treatment of relapsing or refractory acute leukemia with a lysine methyltransferase 2A gene (also known as the mixed lineage leukemia gene) translocation in adults and pediatric patients.
-
Acoramidis Tablets (Attruby)
The U.S. Food and Drug Administration has approved acoramidis, an oral drug for the treatment of transthyretin-related amyloid cardiomyopathy.
-
Sulopenem Etzadroxil and Probenecid (Orlynvah)
The U.S. Food and Drug Administration has approved a combination of sulopenem and probenecid for the treatment of uncomplicated urinary tract infections.